Form 4: Aspira Women's Health Director Stefanie L. Cavanaugh Reports Stock Transactions
SEC Form 4 Filing
Director Stefanie L. Cavanaugh of Aspira Women's Health Inc. reports the vesting and conversion of restricted stock units into common stock.
Summary
- On March 31, 2025, Stefanie L. Cavanaugh, a director of Aspira Women's Health Inc., reported the vesting of 5,938 restricted stock units (RSUs) which converted into common stock.
- These RSUs were part of a grant of 23,750 RSUs awarded on August 22, 2024, with 5,938 vesting on March 31, 2025.
- Following the transaction, Cavanaugh directly owns 72,789 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider transactions, which is neutral in sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects the vesting of previously granted equity compensation.
Key Dates
| Date | Description |
|---|---|
| 08/22/2024 | Reporting person was granted 23,750 RSUs |
| 08/26/2024 | Previous Form 4 filed with the SEC reporting the grant of RSUs |
| 03/31/2025 | 5,938 RSUs vested and converted into common stock |
| 04/01/2025 | Date of signature on the Form 4 |
Keywords
Aspira Women's Health, Director, Stock Transaction, Restricted Stock Units, Common Stock, Vesting, Form 4, Cavanaugh
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.